Department of Pathology, Faculty of General Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Department of Laboratory Medicine, Faculty of General Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Int J Mol Sci. 2024 Jul 22;25(14):8003. doi: 10.3390/ijms25148003.
The clinical impact of therapy-related acute leukemias is increasing with the extension of cancer-related survival; however, the origins remain largely unknown. Acute erythroleukemia (AEL), a rare unfavorable type of myeloid neoplasia, may also develop secondary to cytotoxic therapy. The disorder is featured by specific genetic alterations, most importantly multi-allelic mutations of the gene. While AEL might appear as a part of the therapy-related MDS/AML, spectrum information regarding the genetic complexity and progression is largely missing. We present two AEL cases arising after cytotoxic therapy and melphalan-based myeloablation/autologous peripheral stem cell transplantation due to multiple myeloma (MM). As stated, multiple pathogenic variants were present unrelated to preexisting MM, in parallel with uninvolved/wild-type hemopoiesis. Potential mechanisms of leukemic transformation are discussed, which include (1) preexisting preneoplastic hemopoietic stem cells (HSC) serving as the common origin for both MM and AEL, (2) the generation and intramedullary survival of p53-deficient post-chemotherapy HSCs, (3) reinoculation of mobilized autologous mutated HSCs, and (4) melphalan treatment-related late-onset myelodysplasia/leukemia with newly acquired mutations.
治疗相关急性白血病的临床影响随着癌症相关生存的延长而增加;然而,其起源在很大程度上仍然未知。急性红白血病(AEL)是一种罕见的不利类型的髓系肿瘤,也可能继发于细胞毒性治疗。该疾病的特征是特定的遗传改变,最重要的是基因的多等位基因突变。虽然 AEL 可能出现在治疗相关 MDS/AML 的一部分,但关于遗传复杂性和进展的信息在很大程度上缺失。我们提出了两个由于多发性骨髓瘤(MM)而接受细胞毒性治疗和马法兰为基础的骨髓清除/自体外周干细胞移植后发生的 AEL 病例。如前所述,存在与先前存在的 MM 无关的多个致病性变异体,同时伴有未受累/野生型造血。讨论了白血病转化的潜在机制,包括(1)作为 MM 和 AEL 共同起源的预先存在的肿瘤性造血干细胞(HSC),(2)化疗后缺乏 p53 的 HSC 的产生和骨髓内存活,(3)动员的自体突变 HSC 的再植入,以及(4)马法兰治疗相关的迟发性骨髓增生异常/白血病伴新获得的变异体。